New challenges for a second-generation low-molecular-weight heparin: Focus on bemiparin

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 5, 2010, Pages 625-634

  Martínez Gonzlez, José ^a   Rodríguez, Cristina ^a  

^a Institut Català de Ciències Cardiovasculars   (Spain)

Author keywords

Bemiparin; Deep venous thrombosis; Low molecular weight heparin; Prophylaxis; Pulmonary embolism; Treatment; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BEMIPARIN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; PROTHROMBIN; REVIPARIN; TINZAPARIN;

ADJUVANT THERAPY; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; BLEEDING; BLOOD CLOTTING; CANCER PATIENT; COST EFFECTIVENESS ANALYSIS; DEATH; DEEP VEIN THROMBOSIS; DIABETIC FOOT; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; EXTRACORPOREAL CIRCULATION; HEART INFARCTION; HEMODIALYSIS; HUMAN; LUNG SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOSIS; TOTAL KNEE REPLACEMENT; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; CHEMISTRY, PHARMACEUTICAL; DIABETIC FOOT; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PROTHROMBIN; VENOUS THROMBOEMBOLISM;

EID: 77952235069     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.35     Document Type: Review

References (54)

1. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of Venous Thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl.), 381S-453S (2008).
2. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am. J. Med. 119(1), 60-68 (2006). (Pubitemid 43117468)
3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 5(3), 632-634 (2007).
4. Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler. Thromb. Vasc. Biol. 29(3), 316-320 (2009).
5. Segal JB, Streiff MB, Hofmann LV, Thornton K, Bass EB. Management of venous thromboembolism: a systematic review for a practice guideline. Ann. Intern. Med. 146(3), 211-222 (2007).
6. Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. 354(14), 1477-1488 (2006).
7. Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert Rev. Cardiovasc. Ther. 5(3), 387-399 (2007).
8. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349(2), 146-153 (2003).
9. Khosravi-Shahi P, Pérez-Manga G. International recommendations for the prevention and treatment of venous thromboembolism associated with cancer. Clin. Drug. Investig. 29(10), 625-633 (2009).
10. Nightingale SL. From the Food and Drug Administration. JAMA 270(14), 1672 (1993).
11. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119(1 Suppl.), 64S-94S (2001).
12. Ryan TJ, Antman EM, Brooks NH et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J. Am. Coll. Cardiol. 34(3), 890-911 (1999).
13. Planès A. Review of bemiparin sodium - a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin. Pharmacother. 4(9), 1551-1561 (2003).
14. Martínez-González J, Vila L, Rodríguez C. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism. Expert Rev. Cardiovasc. Ther. 6(6), 793-802 (2008).
15. Rocha E, Imberti D, Paschina E. Low-molecular-weight heparins: before or after surgery? New concepts and evidence: congress report from the Sigma Tau/ROVI Satellite Symposium (Rome, Italy, 13 November 2006). Clin. Drug Investig. 27(5), 357-366 (2007).
16. Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs 63(21), 2357-2377 (2003).
17. Depasse F, González de Suso MJ, Lagoutte I, Fontcuberta J, Borrell M, Samama MM. Comparative study of the pharmacokinetic profiles of two LMWH-bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)-administered subcutaneously to healthy male volunteers. Thromb. Res. 109(2-3), 109-117 (2003).
18. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J. Thromb. Haemost. 5(5), 955-962 (2007).
19. Antonijoan RM, Rico S, Martínez- González J et al. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 47, 726-732 (2009).
20. Christidou FN, Frangia TK, Bamichas GI et al. Comparison of two low-molecular weight heparins (LMWH), tinzaparin and bemiparin, during hemodialysis. Int. J. Clin. Pharmacol. Ther. 43(7), 335-338 (2005).
21. Borrell M, Antonijoan RM, Ortiz R et al. Pharmacokinetic profile of two LMWH: bemiparin 3500 IU and enoxaparin 4000 IU after sc administration in healthy volunteers (18th Congress of the International Society of Thrombosis and Haemostasis. Paris, France, 2001). Thromb. Haemost. 86(Suppl.), CD3578 (2001).
22. Falkon L, Garí M, Sáenz-Campos D, Antonijoan R, Barbanoj M, Fontcuberta J. Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH(RO-11) in healthy subjects. Thromb. Haemost. 73(4), 728-729 (1995).
23. Falkon L, Garí M, Barbanoj M, Amiral J, Fontcuberta J. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, bemiparin, at therapeutic sc doses. Blood Coagul. Fibrinolysis 9(2), 137-141 (1998).
24. Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomized trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Thromb. Haemost. 83, 523-529 (2000).
25. Navarro-Quilis A, Castellet E, Rocha E et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J. Thromb. Haemost. 1(3), 425-432 (2003).
26. Honorato J, Gómez-Outes A, Navarro- Quilis A, Martínez- González J, Rocha E, Planès A. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 22(13), 885-894 (2004).
27. Abad JI, Gómez-Outes A, Martínez- González J et al. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery. Arch. Orthop. Trauma Surg. 127(8), 665-670 (2007).
28. Otero-Fernández R, Gómez-Outes A, Martínez- González J et al. Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice. Clin. Appl. Thromb. Hemost. 14(1), 75-83 (2008).
29. Vavken P, Lunzer A, Grohs JG. A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. Wien. Klin. Wochenschr. 121(13-14), 454-458 (2009).
30. Balibrea JL, Altimiras J, Larruzea I et al. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. Int. J. Surg. 5(2), 114-119 (2007).
31. Constans M, Santamaria A, Mateo J, Pujol N, Souto JC, Fontcuberta J. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int. J. Clin. Pract. 61(2), 212-217 (2007).
32. Miras-Parra F, Navascués-Martínez E, Gómez-Outes A et al. Utilisation and safety of bemiparin, a low-molecular-weight heparin, in medical patients: a prospective, uncontrolled cohort study. Clin. Drug Investig. 25(7), 463-472 (2005).
33. Prieto Seva AJ. Safety and effectiveness of bemiparin in the prevention of venous thromboembolic disease in nursing home patients. Rev. Esp. Geriatr. Gerontol. 42, 20-26 (2007).
34. Rodríguez-Mañas L, Gómez-Huelgas R, Monteagudo G, Maeso R, Gómez-Outes A, Martínez-González J. Bemiparin thromboprophylaxis in elderly medical patients: the ANCIANOS study. J. Thromb. Haemost. 5(Suppl. 2), P-T-671 (2007).
35. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch. Intern. Med. 164(12), 1319-1326 (2004).
36. Spyropoulos AC, Turpie AG. Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Curr. Opin. Pulm. Med. 11(5), 373-379 (2005).
37. Kakkar VV, Gebska M, Kadziola Z et al. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb. Haemost. 89(4), 674-680 (2003).
38. Gómez-Outes A, Rocha E, Martínez- González J, Kakkar VV. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics 24(1), 81-92 (2006).
39. Santamaría A, Juárez S, Reche A et al. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. Int. J. Clin. Pract. 60(5), 518-525 (2006).
40. Lecumberri R, Rosario E, Pacho J, Rocha E; FLEBUS Investigators. Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study. J. Thromb. Haemost. 4(11), 2504-2508 (2006).
41. Boulton AJ, Vileikyte L, Ragnarson- Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 366(9498), 1719-1724 (2005).
42. Rullan M, Cerdà L, Frontera G, Masmiquel L, Llobera J. Treatment of chronic diabetic foot ulcers with bemiparin: a randomized, triple-blind, placebo-controlled, clinical trial. Diabet. Med. 25(9), 1090-1095 (2008).
43. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer. Drug. Dev. Res. 67(2), 166-174 (2006).
44. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. Modulation of gastrointestinal permeability of low-molecular-weight heparin by l-arginine: in vivo and in vitro evaluation. J. Pharm. Pharmacol. 58(5), 591-598 (2006).
45. Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J. Control. Release 113(1), 38-42 (2006).
46. Lamprecht A, Ubrich N, Maincent P. Oral low molecular weight heparin delivery by microparticles from complex coacervation. Eur. J. Pharm. Biopharm. 67(3), 632-638 (2007).
47. Lanke SS, Gayakwad SG, Strom JG, D'Souza MJ. Oral delivery of low molecular weight heparin microspheres prepared using biodegradable polymer matrix system. J. Microencapsul. S26(6), 493-500 (2009).
48. Scala-Bertola J, Gajdziok J, Rabisková M et al. Pellets for oral administration of low-molecular-weight heparin. Drug Dev. Ind. Pharm. 35(12), 1503-1510 (2009).
49. Scala-Bertola J, Rabiskova M, Lecompte T, Bonneaux F, Maincent P. Granules in the improvement of oral heparin bioavailability. Int. J. Pharm. 374(1-2), 12-16 (2009).
50. Siragusa S, Arcara C, Malato A et al. Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann. Oncol. 16(Suppl. 4), iv136- iv139 (2005).
51. Agnelli G, Gussoni G, Bianchini C et al.; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 10(10), 943-949 (2009).
52. Calderero Aragón V, de Gregorio Ariza MA, Pazo Cid R et al. Role of low molecular weight heparins in prophylaxis of thromboembolic events on oncological patients with indwelling central venous catheter. Med. Clin. (Barc). 133(10), 365-370 (2009).
53. Rashid ST, Thursz MR, Razvi NA et al. Venous thromboprophylaxis in UK medical inpatients. J. R. Soc. Med. 98(11), 507-512 (2005).
54. Arbit E, Goldberg M, Gomez-Orellana I, Majuru S. Oral heparin: status review. Thromb. J. 4, 6 (2006).